Jasper reports 93% clinical response rate in SPOTLIGHT study of briquilimab in CIndU

Jasper Therapeutics, Inc.

14 of 15 patients (93%) achieved clinical response; 10 of 12 (83%) in 120mg cohort had complete response.
No serious adverse events or grade 3+ adverse events reported; well-tolerated with no hair/skin changes.
Initial BEACON study data in CSU expected week of January 6, 2025, including 180mg Q8W cohort.
Regulatory clearance obtained to enroll 180mg dose cohort (n=12) in SPOTLIGHT; full results H1 2025.
Significant tryptase reduction observed (66% at 2 weeks) correlating with clinical responses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.